JP2019521990A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521990A5 JP2019521990A5 JP2018565845A JP2018565845A JP2019521990A5 JP 2019521990 A5 JP2019521990 A5 JP 2019521990A5 JP 2018565845 A JP2018565845 A JP 2018565845A JP 2018565845 A JP2018565845 A JP 2018565845A JP 2019521990 A5 JP2019521990 A5 JP 2019521990A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- use according
- item
- subject
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662351234P | 2016-06-16 | 2016-06-16 | |
| US62/351,234 | 2016-06-16 | ||
| PCT/US2017/038003 WO2017218974A2 (en) | 2016-06-16 | 2017-06-16 | Treatment of amd using aav2 variant with aflibercept |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020155475A Division JP2020203941A (ja) | 2016-06-16 | 2020-09-16 | アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019521990A JP2019521990A (ja) | 2019-08-08 |
| JP2019521990A5 true JP2019521990A5 (enExample) | 2020-07-02 |
| JP6814822B2 JP6814822B2 (ja) | 2021-01-20 |
Family
ID=60663653
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018565845A Active JP6814822B2 (ja) | 2016-06-16 | 2017-06-16 | アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置 |
| JP2020155475A Withdrawn JP2020203941A (ja) | 2016-06-16 | 2020-09-16 | アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置 |
| JP2022113865A Pending JP2022137244A (ja) | 2016-06-16 | 2022-07-15 | アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置 |
| JP2024095160A Pending JP2024113193A (ja) | 2016-06-16 | 2024-06-12 | アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置 |
| JP2025152535A Pending JP2025186377A (ja) | 2016-06-16 | 2025-09-12 | アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020155475A Withdrawn JP2020203941A (ja) | 2016-06-16 | 2020-09-16 | アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置 |
| JP2022113865A Pending JP2022137244A (ja) | 2016-06-16 | 2022-07-15 | アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置 |
| JP2024095160A Pending JP2024113193A (ja) | 2016-06-16 | 2024-06-12 | アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置 |
| JP2025152535A Pending JP2025186377A (ja) | 2016-06-16 | 2025-09-12 | アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20190151409A1 (enExample) |
| EP (3) | EP3471780B1 (enExample) |
| JP (5) | JP6814822B2 (enExample) |
| KR (2) | KR20210021113A (enExample) |
| CN (2) | CN117531025A (enExample) |
| AU (3) | AU2017286673B2 (enExample) |
| BR (1) | BR112018076124A2 (enExample) |
| CA (2) | CA3027737A1 (enExample) |
| CY (1) | CY1123697T1 (enExample) |
| DK (2) | DK3795181T3 (enExample) |
| ES (2) | ES3049818T3 (enExample) |
| FI (1) | FI3795181T3 (enExample) |
| HR (2) | HRP20201842T1 (enExample) |
| HU (1) | HUE051953T2 (enExample) |
| IL (3) | IL279919B2 (enExample) |
| LT (2) | LT3471780T (enExample) |
| MX (2) | MX391779B (enExample) |
| PL (1) | PL3795181T3 (enExample) |
| PT (2) | PT3795181T (enExample) |
| RS (2) | RS67328B1 (enExample) |
| SG (1) | SG11201811232XA (enExample) |
| SI (2) | SI3795181T1 (enExample) |
| SM (2) | SMT202100010T1 (enExample) |
| WO (1) | WO2017218974A2 (enExample) |
| ZA (1) | ZA201808538B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2822551T3 (es) | 2014-03-17 | 2021-05-04 | Adverum Biotechnologies Inc | Composiciones y métodos para la expresión génica mejorada en células de los conos |
| FI3265178T3 (fi) | 2015-03-02 | 2026-08-03 | Adverum Biotechnologies Inc | Koostumuksia ja menetelmiä polynukleotidien viemiseksi intravitreaalisesti retinaalisiin tappisoluihin |
| CN117531025A (zh) * | 2016-06-16 | 2024-02-09 | 阿德夫拉姆生物技术股份有限公司 | 使用aav2变体和阿柏西普治疗amd |
| AU2017345470B2 (en) | 2016-10-19 | 2023-08-03 | Adverum Biotechnologies, Inc. | Modified AAV capsids and uses thereof |
| KR102616820B1 (ko) | 2017-03-17 | 2023-12-21 | 애드베룸 바이오테크놀로지스, 인코포레이티드 | 향상된 유전자 발현을 위한 조성물 및 방법 |
| CN107537026A (zh) * | 2017-08-31 | 2018-01-05 | 中山大学中山眼科中心 | Vegf‑b的应用 |
| CN107661492A (zh) * | 2017-08-31 | 2018-02-06 | 中山大学中山眼科中心 | Vegf‑b的新用途 |
| MX2020003945A (es) * | 2017-10-18 | 2020-11-09 | Regenxbio Inc | Tratamiento de enfermedades oculares y cancer de colon metastasico con vegf-trap humano modificado post-traduccionalmente . |
| US11766489B2 (en) * | 2017-11-27 | 2023-09-26 | 4D Molecular Therapeutics, Inc. | Adeno-associated virus variant capsids and use for inhibiting angiogenesis |
| CA3086045A1 (en) | 2017-12-19 | 2019-06-27 | Akouos, Inc. | Aav-mediated delivery of therapeutic antibodies to the inner ear |
| WO2019198084A1 (en) * | 2018-04-12 | 2019-10-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Anti-aging compositions and methods of use |
| RS67656B1 (sr) | 2018-05-10 | 2026-02-27 | Regeneron Pharma | Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora |
| WO2020180951A1 (en) * | 2019-03-04 | 2020-09-10 | Adverum Biotechnologies, Inc. | Sequential intravitreal administration of aav gene therapy to contralateral eyes |
| US20220195462A1 (en) * | 2019-04-24 | 2022-06-23 | Regenxbio Inc. | Fully-human post-translationally modified antibody therapeutics |
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| JP7893739B2 (ja) * | 2019-09-11 | 2026-07-23 | アドヴェラム バイオテクノロジーズ， インコーポレイテッド | アフリベルセプトをコードするａａｖ２バリアントを使用する眼内血管新生疾患を処置する方法 |
| CN114375195A (zh) * | 2019-09-11 | 2022-04-19 | 阿德夫拉姆生物技术股份有限公司 | 使用编码阿柏西普的aav2变体治疗眼新血管疾病的方法 |
| FI4027983T3 (fi) * | 2019-09-11 | 2026-02-03 | Adverum Biotechnologies Inc | Silmän neovaskulaaristen sairauksien hoito afliberseptiä koodaavilla aav2-varianteilla |
| US11400039B2 (en) * | 2020-01-16 | 2022-08-02 | James W. Hill | Changing eye color by gene transduction |
| FR3111913A1 (fr) * | 2020-06-30 | 2021-12-31 | Eyevensys | Construction d’adn pour le traitement de pathologies oculaires |
| CN113952473A (zh) * | 2020-07-21 | 2022-01-21 | 英斯培瑞有限公司 | 用于治疗眼部疾病的组合物和方法 |
| AU2021313839A1 (en) * | 2020-07-21 | 2023-03-23 | FTGEN Corp | Composition and method for treating eye diseases |
| CN113952474A (zh) * | 2020-07-21 | 2022-01-21 | 英斯培瑞有限公司 | 用于治疗眼部疾病的组合物和方法 |
| CN113817775B (zh) * | 2020-08-25 | 2023-02-17 | 南京吉迈生物技术有限公司 | 修饰的阿柏西普、组合物、方法及其在基因治疗中的应用 |
| US20230340529A1 (en) * | 2020-09-03 | 2023-10-26 | University Of Massachusetts | Adeno-associated virus for delivery of kh902 (conbercept) and uses thereof |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| JP2021049374A (ja) * | 2020-12-09 | 2021-04-01 | 株式会社三洋物産 | 遊技機 |
| CN117222400A (zh) * | 2021-04-27 | 2023-12-12 | 阿德夫拉姆生物技术股份有限公司 | 使用编码阿柏西普的aav2变体治疗眼部疾病的方法 |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| WO2023155918A1 (zh) | 2022-02-21 | 2023-08-24 | 上海瑞宏迪医药有限公司 | Vegf结合分子及其医药用途 |
| EP4499669A4 (en) * | 2022-03-30 | 2026-06-24 | Univ Pittsburgh Commonwealth Sys Higher Education | Adenoid-associated viral vectors |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| TW202508610A (zh) | 2023-08-23 | 2025-03-01 | 大陸商上海瑞宏迪醫藥有限公司 | 醫藥組成物及其用途 |
| CN122319247A (zh) * | 2023-09-27 | 2026-06-30 | 匹兹堡大学联邦系统高等教育 | 将核酸递送至视网膜细胞、跨视网膜区递送核酸或将核酸递送至视网膜神经节细胞和/或视网膜色素上皮细胞的腺相关病毒载体 |
| WO2025073297A1 (zh) * | 2023-10-06 | 2025-04-10 | 甘李药业股份有限公司 | 表达抗vegf融合蛋白的aav病毒载体及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3693025T3 (da) * | 2011-04-22 | 2022-01-10 | Univ California | Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf |
| PT2846836T (pt) * | 2012-05-07 | 2019-10-29 | Allergan Inc | Método de tratamento de dmi em doentes refratários à terapia anti-vegf |
| TWI698240B (zh) * | 2012-05-15 | 2020-07-11 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| WO2013188316A1 (en) * | 2012-06-11 | 2013-12-19 | Avalanche Biotechnologies, Inc. | Optical regulation of gene expression in the retina |
| SI4374873T1 (sl) * | 2013-07-12 | 2026-01-30 | Astellas Us Llc | Sredstvo za uporabo pri zdravljenju ali preprečevanju oftalmoloških stanj |
| MX377714B (es) * | 2013-10-18 | 2025-03-11 | Regeneron Pharma | Composiciones que comprenden una combinación de un antagonista de vegf y un anticuerpo anti-ctla-a. |
| FI3265178T3 (fi) * | 2015-03-02 | 2026-08-03 | Adverum Biotechnologies Inc | Koostumuksia ja menetelmiä polynukleotidien viemiseksi intravitreaalisesti retinaalisiin tappisoluihin |
| CN117531025A (zh) * | 2016-06-16 | 2024-02-09 | 阿德夫拉姆生物技术股份有限公司 | 使用aav2变体和阿柏西普治疗amd |
-
2017
- 2017-06-16 CN CN202311530329.4A patent/CN117531025A/zh active Pending
- 2017-06-16 KR KR1020217004488A patent/KR20210021113A/ko not_active Ceased
- 2017-06-16 CN CN201780050283.2A patent/CN109641065A/zh active Pending
- 2017-06-16 LT LTEP17814223.8T patent/LT3471780T/lt unknown
- 2017-06-16 HR HRP20201842TT patent/HRP20201842T1/hr unknown
- 2017-06-16 EP EP17814223.8A patent/EP3471780B1/en active Active
- 2017-06-16 RS RS20251055A patent/RS67328B1/sr unknown
- 2017-06-16 SI SI201731629T patent/SI3795181T1/sl unknown
- 2017-06-16 CA CA3027737A patent/CA3027737A1/en active Pending
- 2017-06-16 IL IL279919A patent/IL279919B2/en unknown
- 2017-06-16 CA CA3312730A patent/CA3312730A1/en active Pending
- 2017-06-16 IL IL314568A patent/IL314568B2/en unknown
- 2017-06-16 JP JP2018565845A patent/JP6814822B2/ja active Active
- 2017-06-16 MX MX2018015512A patent/MX391779B/es unknown
- 2017-06-16 WO PCT/US2017/038003 patent/WO2017218974A2/en not_active Ceased
- 2017-06-16 PL PL20196657.9T patent/PL3795181T3/pl unknown
- 2017-06-16 ES ES20196657T patent/ES3049818T3/es active Active
- 2017-06-16 DK DK20196657.9T patent/DK3795181T3/da active
- 2017-06-16 EP EP25187377.4A patent/EP4671369A3/en active Pending
- 2017-06-16 KR KR1020197001023A patent/KR102218265B1/ko active Active
- 2017-06-16 SI SI201730553T patent/SI3471780T1/sl unknown
- 2017-06-16 DK DK17814223.8T patent/DK3471780T3/da active
- 2017-06-16 HU HUE17814223A patent/HUE051953T2/hu unknown
- 2017-06-16 PT PT201966579T patent/PT3795181T/pt unknown
- 2017-06-16 FI FIEP20196657.9T patent/FI3795181T3/fi active
- 2017-06-16 PT PT178142238T patent/PT3471780T/pt unknown
- 2017-06-16 SG SG11201811232XA patent/SG11201811232XA/en unknown
- 2017-06-16 BR BR112018076124A patent/BR112018076124A2/pt active Search and Examination
- 2017-06-16 AU AU2017286673A patent/AU2017286673B2/en active Active
- 2017-06-16 RS RS20201517A patent/RS61311B1/sr unknown
- 2017-06-16 HR HRP20251248TT patent/HRP20251248T1/hr unknown
- 2017-06-16 LT LTEP20196657.9T patent/LT3795181T/lt unknown
- 2017-06-16 SM SM20210010T patent/SMT202100010T1/it unknown
- 2017-06-16 EP EP20196657.9A patent/EP3795181B1/en active Active
- 2017-06-16 ES ES17814223T patent/ES2840059T3/es active Active
- 2017-06-16 SM SM20250400T patent/SMT202500400T1/it unknown
-
2018
- 2018-12-12 US US16/218,353 patent/US20190151409A1/en not_active Abandoned
- 2018-12-13 IL IL263686A patent/IL263686B/en active IP Right Grant
- 2018-12-13 MX MX2022004786A patent/MX2022004786A/es unknown
- 2018-12-18 ZA ZA2018/08538A patent/ZA201808538B/en unknown
-
2020
- 2020-09-16 JP JP2020155475A patent/JP2020203941A/ja not_active Withdrawn
- 2020-11-30 CY CY20201101133T patent/CY1123697T1/el unknown
-
2021
- 2021-09-01 AU AU2021225178A patent/AU2021225178B2/en active Active
- 2021-09-20 US US17/479,968 patent/US20220265740A1/en active Pending
-
2022
- 2022-07-15 JP JP2022113865A patent/JP2022137244A/ja active Pending
-
2024
- 2024-06-12 JP JP2024095160A patent/JP2024113193A/ja active Pending
-
2025
- 2025-04-28 AU AU2025202930A patent/AU2025202930A1/en active Pending
- 2025-09-12 JP JP2025152535A patent/JP2025186377A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019521989A5 (enExample) | ||
| HRP20201842T1 (hr) | Liječenje amd korištenjem aav2 varijante s afliberceptom | |
| JP2022183183A5 (enExample) | ||
| FI3717636T3 (fi) | Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä | |
| JP2021503914A5 (enExample) | ||
| Barnett et al. | Complications of retinopathy of prematurity treatment | |
| JP2018520646A5 (enExample) | ||
| CN115554418B (zh) | 一种重组腺相关病毒载体的药物组合物及其用途 | |
| CN108368165A (zh) | 用于治疗颅内出血相关症状的方法和组合物 | |
| JP2018517773A (ja) | ＩｇＧＦｃドメインを有する融合タンパク質の安定な液状製剤 | |
| JP2018527941A5 (enExample) | ||
| JP2018509154A5 (enExample) | ||
| JP2019509750A (ja) | 生弱毒化アルファウイルス構築物及び方法、ならびにそれらの使用 | |
| US11000577B2 (en) | Compositions and methods for treating neonatal biliary atresia | |
| JP2020510648A5 (enExample) | ||
| JP2023515916A (ja) | 神経損傷及び関連障害を治療するための方法 | |
| CN117180455A (zh) | 腺相关病毒药物组合物及其用途 | |
| Aziz et al. | Review of gene therapy clinical trials for retinal diseases | |
| TWI788779B (zh) | 一種治療病毒性肺炎的方法和藥物 | |
| US20180000892A1 (en) | Methods and pharmaceutical compositions for the treatment of ischemic conditions | |
| JP2023525257A (ja) | 脊髄性筋萎縮症を治療する方法及び薬剤 | |
| CN119909180A (zh) | 一种治疗肌萎缩侧索硬化的方法和药物 | |
| JP7850132B2 (ja) | ＳＡＲＳ－ＣｏＶ－２感染患者におけるアウトカムを改善するための吸入インターフェロン－ベータ | |
| CN118831152A (zh) | 导管素抗菌肽在缺血性脑卒中药物中的应用 | |
| Ratra | Commentary: Switching of anti-vascular endothelial growth factor agents in refractory diabetic macular edema |